Concepedia

Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial

Duncan Porter, Jurgen van Melckebeke, James Dale, Claudia‐Martina Messow, Alex McConnachie, Andrew Walker, Robin Munro, John McLaren, Euan McRorie, Jon Packham,

The Lancet · 2016 · 119 citations · 17 references

DOIFull text

Open access

Concepts

References

17

The PREMIER study: A multicenter, randomized, double‐blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment

Ferdinand C. Breedveld, Michael H. Weisman, Arthur F. Kavanaugh et al. · Arthritis & Rheumatism · 2005 · 1.8K citations

, , +17

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

Josef S Smolen, Robert Landewé, Ferdinand C. Breedveld et al. · Annals of the Rheumatic Diseases · 2013 · 1.8K citations · Full text

, , +15

Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeks

Stanley Cohen, Paul Emery, Maria Greenwald et al. · Arthritis & Rheumatism · 2006 · 1.6K citations

, , +16

Development and validation of the european league against rheumatism response criteria for rheumatoid arthritis: Comparison with the preliminary american college of rheumatology and the world health organization/international league against rheumatism criteria

Anke M. van Gestel, M.L.L. Prevoo, Martin A. van't Hof et al. · Arthritis & Rheumatism · 1996 · 1.6K citations

, , +17

Etanercept Therapy in Rheumatoid Arthritis

Larry W. Moreland · Annals of Internal Medicine · 1999 · 1.4K citations

, , +14